Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) EBIT (2018 - 2025)

TransMedics (TMDX) has 8 years of EBIT data on record, last reported at -$64.7 million in Q4 2025.

  • For Q4 2025, EBIT fell 848.84% year-over-year to -$64.7 million; the TTM value through Dec 2025 reached $22.6 million, down 39.78%, while the annual FY2025 figure was $22.6 million, 39.78% down from the prior year.
  • EBIT reached -$64.7 million in Q4 2025 per TMDX's latest filing, down from $23.3 million in the prior quarter.
  • Across five years, EBIT topped out at $36.6 million in Q2 2025 and bottomed at -$64.7 million in Q4 2025.
  • Average EBIT over 5 years is -$2.0 million, with a median of -$3.8 million recorded in 2022.
  • Peak YoY movement for EBIT: skyrocketed 1480.57% in 2024, then tumbled 848.84% in 2025.
  • A 5-year view of EBIT shows it stood at -$11.3 million in 2021, then soared by 40.16% to -$6.8 million in 2022, then soared by 138.4% to $2.6 million in 2023, then soared by 232.08% to $8.6 million in 2024, then crashed by 848.84% to -$64.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$64.7 million in Q4 2025, $23.3 million in Q3 2025, and $36.6 million in Q2 2025.